Galectin-3 Inhibitors Suppress Anoikis Resistance and Invasive Capacity in Thyroid Cancer Cells
Accumulating evidence suggests that galectin-3 is a histologic marker of thyroid cancer. However, the pharmacological lectin-based approach has not been well studied. In the present study, we aimed to investigate the therapeutic potential of novel galectin-3 inhibitors by treating thyroid cancer cel...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2021/5583491 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550572872433664 |
|---|---|
| author | Jie-Jen Lee Yi-Chiung Hsu Ying-Syuan Li Shih-Ping Cheng |
| author_facet | Jie-Jen Lee Yi-Chiung Hsu Ying-Syuan Li Shih-Ping Cheng |
| author_sort | Jie-Jen Lee |
| collection | DOAJ |
| description | Accumulating evidence suggests that galectin-3 is a histologic marker of thyroid cancer. However, the pharmacological lectin-based approach has not been well studied. In the present study, we aimed to investigate the therapeutic potential of novel galectin-3 inhibitors by treating thyroid cancer cells with different concentrations of GB1107 or TD139. At high doses, TD139, but not GB1107, reduced cell viability and clonogenicity of thyroid cancer cells. TD139 induced apoptosis of thyroid cancer cells, as evident by an increase in the percentage of sub-G1 cells on cell cycle analysis, caspase-3 activation, and PARP1 cleavage. Either GB1107 or TD139 significantly inhibited cell coherence and counteracted anoikis resistance. Both inhibitors decreased migratory and invasive abilities in a dose-dependent manner. Furthermore, GB1107 and TD139 treatment attenuated AKT phosphorylation and decreased the expression of β-catenin and MMP2. In conclusion, these novel galectin-3 inhibitors suppressed the anoikis resistance, motility, and invasive capacity of thyroid cancer cells at least partly through the AKT/β-catenin pathway. Galectin-3 inhibitors are potentially suitable for preclinical evaluation of treatment and/or prevention of metastatic spread in thyroid cancer. |
| format | Article |
| id | doaj-art-8fa764fbed074f5db6b1c178905b56c4 |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-8fa764fbed074f5db6b1c178905b56c42025-02-03T06:06:28ZengWileyInternational Journal of Endocrinology1687-83371687-83452021-01-01202110.1155/2021/55834915583491Galectin-3 Inhibitors Suppress Anoikis Resistance and Invasive Capacity in Thyroid Cancer CellsJie-Jen Lee0Yi-Chiung Hsu1Ying-Syuan Li2Shih-Ping Cheng3Department of Surgery, MacKay Memorial Hospital and Mackay Medical College, Taipei 104215, TaiwanDepartment of Biomedical Sciences and Engineering, National Central University, Taoyuan City 320317, TaiwanDepartment of Medical Research, MacKay Memorial Hospital, Taipei 104215, TaiwanDepartment of Surgery, MacKay Memorial Hospital and Mackay Medical College, Taipei 104215, TaiwanAccumulating evidence suggests that galectin-3 is a histologic marker of thyroid cancer. However, the pharmacological lectin-based approach has not been well studied. In the present study, we aimed to investigate the therapeutic potential of novel galectin-3 inhibitors by treating thyroid cancer cells with different concentrations of GB1107 or TD139. At high doses, TD139, but not GB1107, reduced cell viability and clonogenicity of thyroid cancer cells. TD139 induced apoptosis of thyroid cancer cells, as evident by an increase in the percentage of sub-G1 cells on cell cycle analysis, caspase-3 activation, and PARP1 cleavage. Either GB1107 or TD139 significantly inhibited cell coherence and counteracted anoikis resistance. Both inhibitors decreased migratory and invasive abilities in a dose-dependent manner. Furthermore, GB1107 and TD139 treatment attenuated AKT phosphorylation and decreased the expression of β-catenin and MMP2. In conclusion, these novel galectin-3 inhibitors suppressed the anoikis resistance, motility, and invasive capacity of thyroid cancer cells at least partly through the AKT/β-catenin pathway. Galectin-3 inhibitors are potentially suitable for preclinical evaluation of treatment and/or prevention of metastatic spread in thyroid cancer.http://dx.doi.org/10.1155/2021/5583491 |
| spellingShingle | Jie-Jen Lee Yi-Chiung Hsu Ying-Syuan Li Shih-Ping Cheng Galectin-3 Inhibitors Suppress Anoikis Resistance and Invasive Capacity in Thyroid Cancer Cells International Journal of Endocrinology |
| title | Galectin-3 Inhibitors Suppress Anoikis Resistance and Invasive Capacity in Thyroid Cancer Cells |
| title_full | Galectin-3 Inhibitors Suppress Anoikis Resistance and Invasive Capacity in Thyroid Cancer Cells |
| title_fullStr | Galectin-3 Inhibitors Suppress Anoikis Resistance and Invasive Capacity in Thyroid Cancer Cells |
| title_full_unstemmed | Galectin-3 Inhibitors Suppress Anoikis Resistance and Invasive Capacity in Thyroid Cancer Cells |
| title_short | Galectin-3 Inhibitors Suppress Anoikis Resistance and Invasive Capacity in Thyroid Cancer Cells |
| title_sort | galectin 3 inhibitors suppress anoikis resistance and invasive capacity in thyroid cancer cells |
| url | http://dx.doi.org/10.1155/2021/5583491 |
| work_keys_str_mv | AT jiejenlee galectin3inhibitorssuppressanoikisresistanceandinvasivecapacityinthyroidcancercells AT yichiunghsu galectin3inhibitorssuppressanoikisresistanceandinvasivecapacityinthyroidcancercells AT yingsyuanli galectin3inhibitorssuppressanoikisresistanceandinvasivecapacityinthyroidcancercells AT shihpingcheng galectin3inhibitorssuppressanoikisresistanceandinvasivecapacityinthyroidcancercells |